What A Dreamforce Conference Survey Had To Say About Salesforce
Patrick Walravens of JMP Securities maintained an Outperform rating on salesforce.com, inc. (NYSE: CRM) with an unchanged $92 price target after attending the company's "Dreamforce" user conference last week.
Walravens took advantage of the conference to ask over a dozen of salesforce.com's partners four key questions, and the answers helped reinforce the analyst's bullish thesis.
No. 1: Has Salesforce Saturated Its Core Sales Cloud Market?
The analyst asked companies if salesforce.com has saturated its core Sales Cloud market. Of the 11 companies who responded, five said yes and six said no.
Some of the comments from participants include:
No. 2: Will Einstein Be A Disappointment?
The analyst asked participants if salesforce.com's artificial intelligence-branded offering, Einstein, will be a failure.
Among the 10 companies that answered, four said yes and six said no.
Some of the comments from participants include:
No. 3: Would An Acquisition Of Twitter Be Viewed Favorably?
The analyst received responses from 12 companies when asked if an acquisition of Twitter Inc (NYSE: TWTR) would be viewed favorably.
Four of the responses said an acquisition would be viewed favorably and eight suggested a positive outcome is unlikely.
Some of the comments from participants include:
No. 4: What Is The Tone Of The Business?
Finally, the analyst asked if the tone of salesforce.com's business is good or bad. A perfect 11 of the 11 companies who responded were positive on salesforce.com's tone.
One of the comments from participants was:
At last check, salesforce.com was up 6.46 percent at $75.47.
Full ratings data available on Benzinga Pro.
Do you have ideas for articles/interviews you'd like to see more of on Benzinga? Please email feedback@benzinga.com with your best article ideas. One person will be randomly selected to win a $20 Amazon gift card!
Latest Ratings for CRM
Date | Firm | Action | From | To |
---|---|---|---|---|
Mar 2022 | Wedbush | Maintains | Outperform | |
Mar 2022 | Canaccord Genuity | Maintains | Buy | |
Mar 2022 | Raymond James | Maintains | Strong Buy |
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Analyst Color Long Ideas News Price Target Reiteration Events Analyst Ratings Movers Best of Benzinga